Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Synthetic nargenicin and monobactam scaffolds: MerckRecent Research Landscape

Bacterial resistance to standard treatments renders traditional antibiotics ineffective, driving up mortality and healthcare costs. These innovations target the MsbA lipid flippase mechanism to disrupt outer membrane biogenesis and restore pathogen susceptibility.

What technical problems is Merck addressing in Synthetic nargenicin and monobactam scaffolds?

Bacterial multidrug resistance

(8)evidences

Existing antibiotic therapies fail against evolving resistant strains and deep-seated intrapulmonary infections. Overcoming these defense mechanisms restores clinical efficacy in life-threatening infections.

Pathogen antibiotic resistance

(5)evidences

Existing antibacterial agents face diminishing efficacy due to evolving microbial defense mechanisms. Developing novel scaffolds overcomes therapeutic failure in treating multi-drug resistant infections.